A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers.
A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers.
复制标题
DOI：
10.1038/s43856-021-00067-3
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Gillet, Laurent
中科院分区：
文献类型：
--
作者：
Saegerman, Claude;Diep, Anh Nguyet;Renault, Veronique;Donneau, Anne-Francoise;Stamatakis, Lambert;Coppieters, Wouter;Michel, Fabienne;Breuer, Christophe;Dandoy, Margaux;Ek, Olivier;Gourzones, Claire;Schyns, Joey;Goffin, Emeline;Minner, Frederic;Durkin, Keith;Artesi, Maria;Bours, Vincent;Bureau, Fabrice;Gillet, Laurent
在COVID-19大流行期间，养老院（NH）居民因其年龄和潜在合并症而受到严重影响。NHS的感染和爆发最有可能是由受感染的工人引发的。对无症状的卫生工作者进行筛查可以防止危险接触和病毒传播给居民。这项研究通过每周唾液RT-qPCR检测，检查了BNT 162 b2 mRNA COVID-19（Comirnaty®; BioNTech和辉瑞）疫苗接种对NH工人唾液分泌SARS-CoV-2的影响。于2021年2月初，在瓦隆区（比利时）的99家NH中进行了为期2个月的队列研究。三种工人，即：每周随访未接种BNT 162 b2 mRNA COVID-19疫苗的受试者（n = 1618）、接种一剂疫苗的受试者（n = 1454）和接种两剂疫苗的受试者（n = 2379）。他们的唾液样本用于监测SARS-CoV-2的脱落。对所有阳性样本进行测序和基因分型，以鉴定流行的野生型病毒或相关变体。在第二次给药后，工人唾液样本中SARS-CoV-2排泄的保护分数估计为1周时0.90（95%CI：0.18; 0.99）和8周时0.83（95%CI：0.54; 0.95）。我们观察到更多的循环SARS-CoV-2和更大的变异性的病毒载量在未接种疫苗的组相比，接种疫苗的组。这项实地队列研究提高了我们对mRNA BNT 162 b2 COVID-19疫苗对接种疫苗的NH工作人员唾液标本中病毒脱落的有效性的认识，有助于更好地制定公共卫生干预和管理决策。护理院尤其受到COVID-19疫情的影响，带来了毁灭性的后果。因此，对护理之家工作人员进行SARS-CoV-2感染筛查有助于预防病毒传播。它还有助于确定已在该人群中广泛实施的疫苗接种是否能有效减少SARS-CoV-2感染数量。为此，我们在两个月的时间内测试了比利时瓦隆区99家养老院工人的唾液样本。一些工人没有接种疫苗，其他人接种了一剂或两剂辉瑞-BioNTech BNT 162 b2疫苗。我们发现，与未接种疫苗的个体相比，完全接种疫苗的个体可以显着预防SARS-CoV-2感染。这些发现有助于提供证据证明BNT 162 b2疫苗接种是限制养老院工作人员感染的有效措施。Saegerman等人在比利时的一组养老院工作人员中进行了唾液SARS-CoV-2检测，这些工作人员要么未接种疫苗，要么接受了一剂或两剂BNT 162 b2 mRNA疫苗。作者表明，接种疫苗可以防止SARS-CoV-2进入唾液，并观察到未接种疫苗组的病毒载量变化更大。
Nursing home (NH) residents have been severely affected during the COVID-19 pandemic because of their age and underlying comorbidities. Infection and outbreaks in NHs are most likely triggered by infected workers. Screening for asymptomatic NH workers can prevent risky contact and viral transmission to the residents. This study examined the effect of the BNT162b2 mRNA COVID‑19 (Comirnaty®; BioNTech and Pfizer) vaccination on the saliva excretion of SARS-CoV-2 among NH workers, through weekly saliva RT-qPCR testing. A 2-month cohort study was conducted among 99 NHs in the Walloon region (Belgium), at the start of February 2021. Three groups of workers, i.e., non-vaccinated (n = 1618), one-dosed vaccinated (n = 1454), and two-dosed vaccinated (n = 2379) of BNT162b2 mRNA COVID‑19 vaccine, were followed-up weekly. Their saliva samples were used to monitor the shedding of SARS-CoV-2. All positive samples were sequenced and genotyped to identify the circulating wild-type virus or variants of concern. The protection fraction against the excretion of the SARS-CoV-2 in the saliva samples of the workers after the second dose is estimated at 0.90 (95% CI: 0.18; 0.99) at 1 week and 0.83 (95% CI: 0.54; 0.95) at 8 weeks. We observe more circulating SARS-CoV-2 and a greater variability of viral loads in the unvaccinated group compared to those of the vaccinated group. This field cohort study advances our knowledge of the efficacy of the mRNA BNT162b2 COVID-19 vaccine on the viral shedding in the saliva specimens of vaccinated NH workers, contributing to better decision-making in public health interventions and management. Nursing homes have been particularly affected by COVID-19 outbreaks with devastating consequences. Screening for SARS-CoV-2 infection in nursing home workers is therefore helpful to prevent transmission of the virus. It is also helpful in determining whether vaccination, which has been widely implemented in this population, is effective at reducing the number of SARS-CoV-2 infections. To this end, we tested saliva samples from workers from 99 nursing homes in the Walloon region of Belgium over a two-month period. Some workers had not been vaccinated and others had received one or two doses of the Pfizer-BioNTech BNT162b2 vaccine. We find that fully vaccinated individuals are significantly protected against SARS-CoV-2 infection compared to non-vaccinated individuals. These findings help to provide evidence that BNT162b2 vaccination is an effective measure to limit the infection of nursing home workers. Saegerman et al. perform saliva SARS-CoV-2 testing in a cohort of nursing home workers in Belgium who are either unvaccinated or have received one or two doses of the BNT162b2 mRNA vaccine. The authors show that vaccination protects against shedding of SARS-CoV-2 into saliva and observe greater variability in viral load in the unvaccinated group.